Deshi launched its Hong Kong stock IPO today, becoming the "first stock of the medical imaging industry."

Hangzhou Deshun Biotechnology Co., Ltd. has officially launched its Hong Kong IPO, with plans to be listed on the Main Board of the Hong Kong Stock Exchange on March 30. The IPO aims to issue 7,999,200 H shares, with a price range of HK$95.6 to HK$112.5 per share. Hong Kong public offering accounts for 10%, while international offering accounts for 90%, with a maximum fundraising of approximately HK$900 million. Deshun is a medical device company specializing in the development of medical imaging products and services. Based on the 2024 revenue calculation, it holds the largest market share in the field of chromosome karyotype analysis in China, breaking the monopoly of international manufacturers. Its self-developed medical imaging platform model iMedImage can cover over 90% of clinical medical imaging scenarios. The company has built a diversified business structure of "medical imaging software + medical equipment + reagents and consumables + technology licensing." The IPO will close on March 25. After listing on the Main Board of the Hong Kong Stock Exchange, Deshun will become the "first stock of the medical imaging model."